Researchers analyzed 168,464 samples to uncover how geographic and technical factors shape global gut microbiome variation, highlighting underrepresented regions and technical biases.

PacBio (NASDAQ: PACB), developer of the world’s most advanced sequencing technologies, and Intus Bio, a leader in microbiome research and discovery, today unveiled GutID, the first commercial human ...

Pacific Biosciences of California, Inc. PACB and Intus Bio, a leader in microbiome research and discovery, recently unveiled ...

“High accuracy, long-read sequencing is essential to Intus Bio’s ability to unlock the microbiome, making GutID not just a test, but a transformative tool for understanding and improving human ...

A primary driver is the growing interest in the human microbiome. The global microbiome sequencing services market is projected to reach $5.5b by 2030 at a compound annual growth rate of 18.1% ...

MENLO PARK, Calif., Jan. 14, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading provider of highly accurate long-read sequencing solutions, announced a significant publication from Radboud ...